Record revenues demonstrate resilience of operations
Update | 3 March 2021
Allergy Therapeutics delivered record interim revenue of £54.0m (+7%, +5% CER) and operating profit pre-R&D of £20.5m during financial H121, emphasising the resilience of its European commercial business despite COVID-19 impacts and the spectre of Brexit. Operationally, the company is also progressing steadily with its pipeline. The G309 exploratory Grass MATA MPL Phase III study is fully enrolled, with most subjects treated ahead of the pollen season; data, anticipated in the autumn, are expected to inform design of the G306 pivotal grass trial (scheduled to start autumn 2022). The ongoing P001 ex vivo peanut allergy biomarker study should read out in the spring, ahead of an FDA pre-IND meeting in calendar H121 and potential IND submission by year end. Allergy Therapeutics’ £48.3m cash balance (at end-December 2020) will fund both the Grass MATA MPL Phase III trial programme and the peanut allergy Phase I trial, with data from these representing material value-inflection points. We upgrade our valuation to £344.5m, equivalent to 53.8p per share.
|Year-end: June 30||2019||2020||2021E||2022E|
|Adj. PBT (£m)||(3.7)||3.5||(6.4)||(4.4)|
|Net Income (£m)||3.5||6.9||(6.2)||(4.1)|
|Adj. EPS (p)||0.5||1.1||(1.0)||(0.6)|
3 March 2021
|Shares in issue||640.8m|
|12 month range||7.0-22.0p|
|Primary exchange||AIM London|
Allergy Therapeutics specialises in the diagnosis and treatment of allergy. The existing European business generates c £80m annual sales. Near-term R&D efforts are focussed on the Pollinex Quattro platform, whilst in the medium-term the VLP platform is highly promising
+44 (0) 20 3637 5043
+44 (0) 20 3637 5041
Table of Contents
Allergy Therapeutics delivered a robust financial and operational performance in H121, with record interim revenues, pre-R&D operating profit, and cash position. Despite the challenges posed by COVID-19 impacts and ongoing uncertainties, plus additional hurdles posed by Brexit, the European commercial business has proved remarkably resilient with growth across all key products and further market share gains. Progress of the high potential development pipeline should switch investor attention to the stream of anticipated news flow connected to major programmes, Grass MATA MPL and VLP-peanut allergy. Study data from both assets is anticipated during 2021, which will help define their future development paths. We upgrade our valuation on the back of solid H121 results and ahead of data points in the spring (peanut ex vivo biomarker results and FDA pre-IND meeting) and autumn (results of the G309 exploratory grass allergy field study). We now value Allergy Therapeutics at £344.5m, or 53.8p/share vs £325m (51p/share) previously.
Allergy Therapeutics commercial business continues to provide a solid base of recurring income despite various headwinds, although the focus in calendar 2021 will be on trial data and clinical progress as key pipeline assets advance to important inflection points. Current cash resources fully fund two key R&D programmes: Grass MATA MPL Phase III and VLP peanut allergy Phase I.
The c 150 patient multi-centre G309 exploratory Grass MATA MPL Phase III field study is fully recruited, with most subjects already treated ahead of the start of the grass pollen season. The highly innovative trial design has not been fully disclosed, as it is based on proprietary cutting-edge concepts in the allergy field. It is known to include evaluation of several different placebo options (including saline), combine several Phase II and Phase III endpoints to support the validation of the regulatory mandated primary endpoint (combined symptom medication score, CSMS, averaged over the peak grass pollen season), and includes extensive biomarker analysis.
First G309 results are expected in autumn 2021 and will be critical in informing and optimising the design of the G306 pivotal grass trial which will support European and FDA filings and potential US approval. In Europe, this will enable wider prescribing, not restricted to a ‘named patient’ basis; in the US, Grass MATA MPL will likely become the first available short-course, subcutaneous, aluminium-free grass allergy immunotherapy. G306 is scheduled to start in autumn 2022, over the 2022/23 allergy season, with an autumn 2023 read out.
VLP-peanut allergy is the first Virus Like Particle-based vaccine in Allergy Therapeutics’ portfolio and addresses a sizeable and underserved market. The ex vivo biomarker study (P001) in collaboration with Imperial College London is progressing well, and manufacturing batch scale up to 400L has been achieved. The P001 study is exploring an extensive array of functional and molecular biomarkers using blood samples from peanut allergy patients to evaluate and confirm the hypoallergic potential of the vaccine candidate and the potency of the immune response induced.
Biomarker study results, expected in spring 2021, will give the first indication of human reaction to the vaccine candidate, and will be used to support further clinical development, including establishing the starting dose of the first-in-human Phase I study. A pre-IND meeting with the FDA has been scheduled for calendar H121, and IND filing is planned for autumn 2021. Assuming no regulatory, or COVID-19 related clinical delays, recruitment into the Phase I study (P101) will begin in early calendar 2022.
Details on the P101 study design are expected to be disclosed following agreement with the FDA. However, it is known that given the high allergenicity of peanut, the P101 study will use a stepwise approach, with the first stage involving healthy volunteers, then proceeding to skin prick tests in peanut allergy patients, before embarking on subcutaneous injection in peanut allergy sufferers.
R&D efforts continue to be directed to working to meet regulatory requirements for the German TAV (Therapy Allergy Ordinance) process, and to addressing similar legislation being implemented by Italy and Spain. The studies being carried out and the data generated will be applicable across the entire EU. We note that Venomil (bee and wasp venom allergy vaccine), already approved in Germany, has recently received regulatory approval in Austria.
Early-stage work with other non-allergy VLP candidates, as well as adjuvant technologies is also ongoing, with the company seeking to secure IP and establish proof of concept for melanoma, asthma, atopic dermatitis, and psoriasis. We await further disclosures on this technology in due course.
Management is executing nicely against its well-articulated strategy: maximising the performance of its existing commercial platform; developing a suite of innovative products that address well-documented needs; and preparing for geographic expansion, notably the US. It is this continued strong performance in Europe that is helping to fund the development of novel R&D programmes, particularly the grass MATA MPL and innovative VLP-based peanut vaccine. These highly differentiated and clinically validated products will, if successful, enable effective penetration into the commercially important US market.
We continue to value Allergy Therapeutics using a sum of the parts model which couples a DCF of the base European commercial business with a pipeline rNPV model of the main developmental stage allergy immunotherapy programmes. In line with our philosophy, we use conservative assumptions throughout and have previously detailed our valuation methodology in our September 2020 Initiation.
On this basis we ascribe a valuation of £344.5m (equivalent to 53.8p per share) to Allergy Therapeutics, with the commercial base business contributing £89.7m (14p/share) and the pipeline an additional £210.3m (32.8p/share). This is a modest upgrade to our prior valuation of £325m (51p/share), comprising £87m (14p/share) for the commercial operations and £204m (32p/share) for the pipeline. Exhibit 1 provides a breakdown of the various components.
Our valuation leaves ample room for upside from various sources. For example, our commercial DCF is based on market growth of 6-7% over the next five years with no market share gains (history would suggest this is arguably over-conservative), coupled with a modest 2% terminal growth rate. However, over the medium term, the registration and approvals of the Pollinex Quattro ranges (currently sold on a ‘named patient basis’) across Europe would remove the current restrictions on promoting these subcutaneous immunotherapy (SCIT) products to a wider physician audience, capturing additional patients. Even modest uptake beyond the traditional prescribers should, especially outside Germany, result in a noticeable uplift in revenue growth.
In a similar timeframe, the US launch of Pollinex Quattro grass would add steadily increasing incremental sales in this new and highly attractive geographic market, boosting revenue growth into double-digits and potentially the high-teens. This would be supported by the broader roll-out of the PQ product range and the VLP peanut vaccine, which could be transformational for Allergy Therapeutics, and represents further upside potential.
Allergy Therapeutics H121 results (six months ended 31 December 2020) indicated record revenues up 7% (+5% CER) to £54.0m (H120: £50.5m), with robust growth across all key products supported by the science-based marketing approach. Sales growth varied geographically, largely influenced by COVID-19 impacts. Growth was stronger in Northern Europe (in particular, Germany, Austria, Netherlands, and Switzerland) where allergy clinics are largely standalone vs a weaker performance in Italy, Spain and the UK, due to closures of hospital-based allergy clinics as resources were diverted to the emergency setting.
Cost of goods increased in absolute terms as higher volumes were sold, translating into increased gross profit of £42.2m (H120: £39.1m), with a 78% gross margin. The continuing pandemic and the evolving responses cloud the H221 outlook, although management anticipate continued net sales growth on H220. Due to the seasonality of allergy treatment, 60-70% of sales are generated in H1; hence a profitable H121 is expected to be followed by a loss-making H2. The H221 gross margin, in common with prior years, will be lower than H1 reflecting lower factory volumes. However, FY21 gross margin will be in line with FY20 due to seasonality and Brexit stock building. As an export business, Brexit has so far been administratively burdensome for Allergy Therapeutics, although the company was well prepared for Brexit implementation (including with increased inventory levels) but continues to adjust and optimise relevant processes.
Operating profit pre-R&D was £20.5m, a record level, up 18.5% (H120: £17.3m), with a pre-R&D operating margin of 38% (H120: 34%). Sales, marketing and distribution costs reflected reduced activity and travel in the period due to COVID-19 (H121: £12.4m vs H120: £13.6m), although these savings were partially offset by higher admin spend (£9.7m vs £8.2m) on compliance and infrastructure.
H121 R&D investment of £4.7m was in line with H120, although the reported figure of £1.3m for the prior period included a £3.2m exceptional received from the Inflamax litigation settlement. Current R&D spend largely reflects the progress of the Grass MATA MPL Phase III programme: the first stage (G309) is fully recruited and on track to complete dosing ahead of the allergy season. R&D expenditure is expected to double in H221 reflecting a more active period in the G309 study, with the bulk of associated costs to be incurred during calendar 2021. Investment is also being directed into pre-IND work for the VLP-peanut allergy programme and the ongoing TAV process.
Cash and equivalents increased to a record balance of £48.3m (vs £37.0m at end-June 2020), representing net cash of £44.5m (£33.2m). Management expects to renew existing banking facilities in August 2021 when they fall due. We again highlight the natural H1 bias to performance and cash generation from operations (ex-R&D) due to the seasonality of the pollen allergy market and anticipate an end-June 2021 cash position of £30.1m.
For FY21 we continue to expect full-year sales of £83.7m (+7%), pre-R&D operating profit of £11.0m, and R&D investment of £15.8m. Non-R&D operating costs should rise broadly in line with sales resulting in a reported operating loss of £4.7m, and net loss of £6.2m. Our forecasts are presented in Exhibit 2.
Trinity Delta Research Limited (“TDRL”; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited (“ED”). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.
ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.
In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.
Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves (‘issuer financed research’) and as such is not deemed to be independent, as defined by the FCA, but is ‘objective’ in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.
This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at www.fisma.org. TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.
Copyright 2021 Trinity Delta Research Limited. All rights reserved.